Literature DB >> 12361920

Thalidomide in the treatment of leprosy.

Steve K Teo1, Ken E Resztak, Michael A Scheffler, Karin A Kook, Jerry B Zeldis, David I Stirling, Steve D Thomas.   

Abstract

Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-alpha produced by monocytes.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12361920     DOI： 10.1016/s1286-4579(02)01645-3

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  26 in total

1.  A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects.

Authors:  Filemon Dela Cruz; Melissa Terry; Igor Matushansky
Journal:  Differentiation       Date:  2012-03-08       Impact factor: 3.880

2.  Selective leukemic-cell killing by a novel functional class of thalidomide analogs.

Authors:  Yun Ge; Idalia Montano; Gabriella Rustici; Wendy J Freebern; Cynthia M Haggerty; Wenwu Cui; Damaris Ponciano-Jackson; G V R Chandramouli; Erin R Gardner; William D Figg; Mones Abu-Asab; Maria Tsokos; Sharon H Jackson; Kevin Gardner
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

Review 3.  The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies.

Authors:  Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield
Journal:  Pharmacogenomics       Date:  2016-12-05       Impact factor: 2.533

Review 4.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 5.  Properties of thalidomide and its analogues: implications for anticancer therapy.

Authors:  Steven K Teo
Journal:  AAPS J       Date:  2005-03-22       Impact factor: 4.009

6.  Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.

Authors:  Ting Liu; Feng Guo; Xiaomin Zhu; Xiangge He; Lin Xie
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

7.  Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.

Authors:  Lei Zhang; Qiaoling Song; Xinxin Zhang; Li Li; Ximing Xu; Xiaohan Xu; Xiaoyu Li; Zhuoya Wang; Yuxi Lin; Xin Li; Mengyuan Li; Fan Su; Xin Wang; Peiju Qiu; Huashi Guan; Yu Tang; Wenfang Xu; Jinbo Yang; Chenyang Zhao
Journal:  Invest New Drugs       Date:  2019-05-14       Impact factor: 3.850

Review 8.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 9.  Lenalidomide in myelodysplastic syndrome and multiple myeloma.

Authors:  Sachin R Shah; Thu M Tran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.